Table 2– Rate of adverse outcomes and value of biomarkers and echocardiography according to the pulmonary embolism severity index (PESI) classes

		PESI class		p-value
	I–II (low risk)	III–IV (intermediate risk)	V (high risk)
Patients	329	179	21
End-points
30-day mortality	2 (0.6)	11 (6.1)	2 (9.5)	<0.001
30-day adverse event	7 (2.1)	15 (8.4)	3 (14.3)	<0.001
Echocardiography and cardiac biomarkers
BNP ng·L⁻¹	44.5 (21.5–146.0)	126.5 (46.0–299.0)	221.0 (130.0–385.0)	<0.001
Cardiac troponin I μg·L⁻¹	0.01 (0.00–0.04)	0.01 (0.00–0.10)	0.03 (0.00–0.19)	<0.01
Right ventricle/left ventricle EDD ratio	0.63 (0.51–0.76)	0.71 (0.56–0.86)	0.59 (0.51–0.88)	0.02

Data are presented as n, n (%) or median (interquartile range), unless otherwise stated. Distributions of deaths and adverse events according to PESI risk class were compared using Chi-squared tests; distributions of markers according to PESI risk class were compared using Kruskall–Wallis tests. BNP: brain natriuretic peptide; EDD: end-diastolic diameter.